...
首页> 外文期刊>Quantitative Imaging in Medicine and Surgery >Contrast-enhanced magnetic resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal cell carcinoma histopathological grade and differentiating fat-poor angiomyolipoma
【24h】

Contrast-enhanced magnetic resonance (MR) T1 mapping with low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) is promising in identifying clear cell renal cell carcinoma histopathological grade and differentiating fat-poor angiomyolipoma

机译:用低剂量钆 - 二亚乙基三胺五乙酸(GD-DTPA)对比增强的磁共振(MR)T1映射在鉴定透明细胞肾细胞癌组织病理学级和分化脂肪贫血血症瘤中有前途

获取原文
           

摘要

Background: This study aimed to identify clear cell renal cell carcinoma (ccRCC) histopathological grade and differentiate it from fat-poor angiomyolipoma (AML). This was achieved through contrast-enhanced magnetic resonance (MR) T1 mapping with intravenous low-dose gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA). Methods: In total, 56 consecutive patients received MR scanning between January 2016 and December 2018 using the pre- and post- contrast-enhanced T1 mapping sequences with low-dose Gd-DTPA (0.036 mmol/kg). RCCs were pathologically proven in 40 patients after surgery and graded according to the International Society of Urological Pathology (ISUP) classification system. Ten AMLs were pathologically proven by surgery histopathology and six AMLs were diagnosed by magnetic resonance imaging (MRI). Patients were followed up for more than half a year. The mean T1 values of the renal lesion and ipsilateral normal renal parenchyma were measured before and after Gd-DTPA administration (T1p and T1e). The reduction of T1 value (T1d) and the ratio of its reduction (T1d %) were calculated and compared. Results: In 40 ccRCCs, higher-grade [International Society of Urologic Pathology (ISUP) grade 3 and 4] and lower-grade (ISUP grade 1 and 2) ccRCCs were noted in 13 and 27 patients, respectively. The mean T1p was 1,514.8±139.4 ms and the mean T1d was 907.7±193.7 ms in the higher-grade ccRCCs, which were significantly higher than in the lower-grade ccRCCs (T1p =1,251.7±151.5 ms and T1d =648.5±218.2 ms, respectively; P0.001). Fat-poor AMLs had higher T1p (1,677.3±104.8 ms) and T1e (865.6±251.5 ms) as compared to ccRCCs (P0.001). Combined T1p + T1d showed the highest area under the curve (AUC) (0.912) in the differentiation of higher-grade ccRCCs from lower-grade ccRCCs (P=0.010). Combined T1p + T1e had the highest AUC (0.956) in the differentiation between ccRCCs and fat-poor AMLs (P=0.010). All T1 mapping metrics could discriminate between normal renal parenchyma and renal lesions (P0.001). No significant difference was found in the T1p and T1e at different parts of the ipsilateral normal renal parenchyma. Interobserver agreement for quantitative longitudinal relaxation time in the T1 maps was excellent. Conclusions: Contrast-enhanced T1 mapping with low-dose Gd-DTPA may provide a more reliable and accurate approach in identifying ccRCCs histopathological grade and differentiating ccRCCs from fat-poor AMLs.
机译:背景:该研究旨在鉴定透明细胞肾细胞癌(CCRCC)组织病理学等级,并将其与脂肪差的血管脂瘤(AML)分化。这是通过用静脉内低剂量钆 - 二亚乙基三胺五乙酸(GD-DTPA)的对比增强的磁共振(MR)T1测绘来实现。方法:共有56名连续患者于2016年1月至2018年12月之间接受MR扫描,使用具有低剂量GD-DTPA(0.036mmol / kg)的前后增强的T1映射序列。 rccs在手术后40例患者病理上被证明,并根据国际泌尿病病理学(ISUP)分类系统的国际社会分级。通过手术组织病理学进行病理上证明,10AML被诊断,通过磁共振成像(MRI)诊断出六个AML。患者随访超过半年。在GD-DTPA给药(T1P和T1E)之前和之后测量肾病变和肾小珠正常肾上实质的平均T1值。计算并比较T1值(T1D)的减少和其还原(T1D%)的比率。结果:在40个CCRCCS中,在13例和27名患者中,分别注意到较高级[国际泌尿病病理学(ISUP)3和4级]和较低级(ISUP级和2和2级)CCRCC。平均T1P为1,514.8±139.4 ms,平均T1D在高级CCRCC中为907.7±193.7ms,显着高于较低级CCRCC(T1P = 1,251.7±151.5 ms和T1D = 648.5±218.2毫秒分别; p <0.001)。与CCRCC相比,脂肪差的AML具有更高的T1P(1,677.3±104.8 ms)和T1e(865.6±251.5 ms)(P <0.001)。组合的T1P + T1D显示曲线下的最高面积(AUC)(0.912),较低级CCRCC的较高级CCRCCs(P = 0.010)。组合的T1P + T1E在CCRCC和脂肪差的AML之间的差异中具有最高的AUC(0.956)(P = 0.010)。所有T1映射度量都可以区分正常的肾脏实质和肾病段(P <0.001)。在同侧正常肾上实质的不同部位的T1P和T1E中发现了没有显着差异。 T1地图中的定量纵向松弛时间的Interobserver协议非常出色。结论:低剂量Gd-DTPA的对比度增强T1映射可以提供更可靠和准确的方法,用于鉴定CCRCCs组织病理学等级并将CCRCC分化来自脂肪差的AML。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号